Comparison of the beta-adrenoceptor blocking activity of oxprenolol, slow release oxprenolol and a combined oxprenolol diuretic preparation.
1 Observations were made in five healthy subjects who exercised before and 2, 3, 6, 8 and 24 h after the oral administration on separate occasions of 160 mg oxprenolol, 160 mg slow release oxprenolol, 160 mg slow release oxprenolol with 0.25 mg cyclopenthiazide and placebo. Blood samples were obtained before and at 1, 2, 3, 6, 8, 12 and 24 h after drug administration and assayed for oxprenolol concentration. 2 The three formulations produced maximum reductions of 29% in the exercise tachycardia 3 to 6 h after drug administration. At 24 h the effects of the three preparations were not significantly different from placebo. 3 There were no significant differences in the plasma concentrations produced by the three formulations during the 24 h period. 4 These observations suggest that the slow release formulations of oxprenolol should be given twice daily to maintain cardiac beta-adrenoceptor blockade throughout a period of 24 h.
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000328:Adult; D003518:Cyclopenthiazide / Q000008:administration & dosage; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D010096:Oxprenolol / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology; D005082:Physical Exertion; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D010096:Oxprenolol; D003518:Cyclopenthiazide